MEVIS MEDICAL SOLUTIONS AG (M3V.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M3V - DE000A0LBFE4 - Common Stock
24.6 EUR
0 (0%)
M3V gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 11 industry peers in the Health Care Technology industry. M3V scores excellent points on both the profitability and health parts. This is a solid base for a good stock. M3V has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
M3V had positive earnings in the past year.
In the past year M3V had a positive cash flow from operations.
Each year in the past 5 years M3V has been profitable.
In the past 5 years M3V always reported a positive cash flow from operatings.
1.2 Ratios
M3V has a better Return On Assets (17.22%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 25.58%, M3V belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 14.00%, M3V belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for M3V is significantly above the industry average of 9.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.22% | ||
| ROE | 25.58% | ||
| ROIC | 14% |
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
1.3 Margins
M3V's Profit Margin of 26.87% is amongst the best of the industry. M3V outperforms 90.91% of its industry peers.
In the last couple of years the Profit Margin of M3V has declined.
Looking at the Operating Margin, with a value of 23.58%, M3V belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
In the last couple of years the Operating Margin of M3V has declined.
With an excellent Gross Margin value of 97.12%, M3V belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
M3V's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.58% | ||
| PM (TTM) | 26.87% | ||
| GM | 97.12% |
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), M3V is creating value.
M3V has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for M3V remains at a similar level compared to 5 years ago.
There is no outstanding debt for M3V. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.63 indicates that M3V is not in any danger for bankruptcy at the moment.
M3V has a Altman-Z score of 4.63. This is amongst the best in the industry. M3V outperforms 90.91% of its industry peers.
There is no outstanding debt for M3V. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.63 |
ROIC/WACC1.92
WACC7.3%
2.3 Liquidity
M3V has a Current Ratio of 1.52. This is a normal value and indicates that M3V is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of M3V (1.52) is comparable to the rest of the industry.
M3V has a Quick Ratio of 1.52. This is a normal value and indicates that M3V is financially healthy and should not expect problems in meeting its short term obligations.
M3V has a Quick ratio of 1.52. This is in the better half of the industry: M3V outperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.52 |
3. Growth
3.1 Past
The earnings per share for M3V have decreased by -7.41% in the last year.
Measured over the past years, M3V shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.74% on average per year.
The Revenue has decreased by -2.14% in the past year.
M3V shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.25% yearly.
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
M3V is valuated reasonably with a Price/Earnings ratio of 9.84.
M3V's Price/Earnings ratio is rather cheap when compared to the industry. M3V is cheaper than 90.91% of the companies in the same industry.
M3V is valuated cheaply when we compare the Price/Earnings ratio to 27.00, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.84 | ||
| Fwd PE | N/A |
4.2 Price Multiples
63.64% of the companies in the same industry are more expensive than M3V, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, M3V is valued cheaply inside the industry as 81.82% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.74 | ||
| EV/EBITDA | 9.25 |
4.3 Compensation for Growth
The excellent profitability rating of M3V may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.86%, M3V has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.25, M3V pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 1.94, M3V pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
5.2 History
The dividend of M3V is nicely growing with an annual growth rate of 24.89%!
Dividend Growth(5Y)24.89%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
M3V pays out 107.89% of its income as dividend. This is not a sustainable payout ratio.
The Dividend Rate of M3V has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP107.89%
EPS Next 2YN/A
EPS Next 3YN/A
FRA:M3V (1/5/2026, 7:00:00 PM)
24.6
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners23.29%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap44.77M
Revenue(TTM)16.97M
Net Income(TTM)4.56M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
Yearly Dividend2.7
Dividend Growth(5Y)24.89%
DP107.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.84 | ||
| Fwd PE | N/A | ||
| P/S | 2.64 | ||
| P/FCF | 15.74 | ||
| P/OCF | 14.23 | ||
| P/B | 2.51 | ||
| P/tB | 2.51 | ||
| EV/EBITDA | 9.25 |
EPS(TTM)2.5
EY10.16%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.56
FCFY6.35%
OCF(TTM)1.73
OCFY7.03%
SpS9.32
BVpS9.79
TBVpS9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number23.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.22% | ||
| ROE | 25.58% | ||
| ROCE | 19.88% | ||
| ROIC | 14% | ||
| ROICexc | 20.72% | ||
| ROICexgc | 20.72% | ||
| OM | 23.58% | ||
| PM (TTM) | 26.87% | ||
| GM | 97.12% | ||
| FCFM | 16.76% |
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
ROICexc(3y)27.89%
ROICexc(5y)26.51%
ROICexgc(3y)27.89%
ROICexgc(5y)26.51%
ROCE(3y)24.36%
ROCE(5y)24.64%
ROICexgc growth 3Y-4.16%
ROICexgc growth 5Y-6.12%
ROICexc growth 3Y-4.16%
ROICexc growth 5Y-6.1%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 227.51% | ||
| Cap/Sales | 1.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 76.1% | ||
| Profit Quality | 62.38% | ||
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.52 | ||
| Altman-Z | 4.63 |
F-Score4
WACC7.3%
ROIC/WACC1.92
Cap/Depr(3y)151.22%
Cap/Depr(5y)111.1%
Cap/Sales(3y)0.98%
Cap/Sales(5y)0.77%
Profit Quality(3y)80.13%
Profit Quality(5y)97.8%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.41%
EBIT growth 3Y-3.25%
EBIT growth 5Y-10.94%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.74%
FCF growth 3Y-32.08%
FCF growth 5Y-14.82%
OCF growth 1Y-46.25%
OCF growth 3Y-29.89%
OCF growth 5Y-13.63%
MEVIS MEDICAL SOLUTIONS AG / M3V.DE FAQ
What is the ChartMill fundamental rating of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to M3V.DE.
What is the valuation status for M3V stock?
ChartMill assigns a valuation rating of 5 / 10 to MEVIS MEDICAL SOLUTIONS AG (M3V.DE). This can be considered as Fairly Valued.
How profitable is MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?
MEVIS MEDICAL SOLUTIONS AG (M3V.DE) has a profitability rating of 8 / 10.
What is the financial health of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?
The financial health rating of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) is 8 / 10.